Overall, in lung cancer, the clinical efficacy of AMPK activation via metformin remains uncertain; promising signals in small studies have been tempered by larger trials showing no clear benefit, indicating a need for better patient selection or combination strategies. This evidence concerns the gene PRKAA1 and lung carcinoma.